Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind placebo-controlled study of ARA 290 for neuropathic symptoms in type 2 diabetes
2012-005590-32Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2013
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic neuropathy and type 2 diabetes mellitus (T2DM) comparing ARA 290 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jan 2013; status: active.
02
Drugs
cibinetide
03
Conditions
diabetic neuropathytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-005590-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005590-32.